- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03530371
Intranasal Dexmedetomidine for Sedated Hearing Testing
Effectiveness of Intranasal Dexmedetomidine for Sedated Auditory Brainstem Response Testing
Auditory brainstem response testing is necessary in children who are not able to be tested by classical audiogram, because of their age or an associated retarded psycho-motor development or behavioral and cognitive troubles.
This test needs a perfect immobility of the child, ideally being asleep. This situation is sometimes impossible to achieve in non-cooperative children.
Currently, in the Pediatric Hospital of Nice, the investigators have to do a general anesthesia to perform quality auditory response tests in this kind of patients.
The alternative to a general anesthesia would be a reliable sedative drug, allowing the performance of this diagnostic exam without the need of a hospitalization.
Dexmedetomidine is a sedative drug with an action on the α2 adrenergic receptors. It causes a rapid sedation, similar to the natural sleep and with minimal secondary effects. The possibility of an intranasal administration, avoids the pain and discomfort of a venous access insertion.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Auditory brainstem response testing is necessary in children who are not able to be tested by classical audiogram, because of their age or an associated retarded psycho-motor development or behavioral and cognitive troubles.
This test needs a perfect immobility of the child, ideally being asleep. This situation is sometimes impossible to achieve in non-cooperative children.
Currently, in the Pediatric Hospital of Nice, the investigators have to do a general anesthesia to perform quality auditory response tests in this kind of patients.
The alternative to a general anesthesia would be a reliable sedative drug, allowing the performance of this diagnostic exam without the need of a hospitalization. An intranasal administration avoids the pain and discomfort of a venous access insertion.
Dexmedetomidine is a sedative drug with an action on the α2 adrenergic receptors. It causes a rapid sedation, similar to the natural sleep and with minimal secondary effects. The treatment will be administrated by intranasal way at a dosage of 2,5µg/ kg in a single administration under continuous cardiorespiratory monitoring for 2 hours..
The objective of this work is to evaluate the effectiveness of intranasal dexmedetomidine in the realization of the auditory brainstem response at the child with a cognitive or behavioral disorder
This study will consist of research involving non-randomized, monocentric prospective interventional for a duration of 30 months. Patients from 1 year of age and under 16 years, in context of suspicion of deafness will be included. In view of active queue of otorhinolaryngology service of Nice University Hospital and taking into account lost sight, the investigators can include 60 patients, to have a representative sample of concerned pediatric population.
The primary endpoint will be the rate of children included in the study who could determine the auditory threshold. The non-determination of this threshold (or the determination by resorting to general anesthesia or sedation of another type) regardless of the cause will be considered a failure.
Despite the lack of specific protocols, the applications of dexmedetomidine in children for many diagnostic procedures have been studied in the past few years.
Any prospective study about the efficacy of dexmedetomidine for auditory brainstem response testing has been yet conducted in children
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Nice, France, 06200
- Hôpitaux Pédiatriques de Nice CHU-Lenval
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Child aged 1 to 15 years old
- American Society Anesthesiologists (ASA) scale patient 1 or 2
- Need to evaluate the child audition in a context of suspicion of deafness, delay of language, global delay of the development, the risk factors of hearing loss
- Impossibility to realize a hearing test by conventional audiogram or behavioral due to a cognitive or behavioral disorder of the child
- Affiliation to social security scheme
- Signature of the authorization documents of the 2 parents or the representative of the parental authority for the participation of the child in the study
Exclusion Criteria:
- Heart disease or heart rhythm disorder
- Pneumopathy or asthmatic crisis in previous 2 weeks in the examination
- Recent used of digoxine or beta-blocker
- Use of anti-epileptic or psychotropic drugs
- Medical history of sleep apnea
- Receptor alpha2 agonist allergy
- Gastrooesophageal reflux disease
- Upper airway abnormality
- Acute cerebrovascular diseases
- Neurologic disorders ( cranial trauma and after neurosurgical operation)
- Recent cerebral vascular accident
- Moyamoya disease
- General anesthesia planned for another procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dexmedetomidine Hydrochloride
sedation of patients to perform auditory test
|
intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
quality of diagnostic
Time Frame: 5 minutes after the realization of auditory test
|
measure the rate of children for who the auditory threshold is obtained with drug sedation condition.
|
5 minutes after the realization of auditory test
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
tolerance of treatment
Time Frame: from drug administration to 24 hours after administration of drug
|
The tolerance will measure by the collection of the following undesirable effects:
These effects will determinate by cardiorespiratory monitoring during the examination. A routine home phone call on D1 will collect information about possible unexpected side effects. |
from drug administration to 24 hours after administration of drug
|
time of correct sedation
Time Frame: from 5 minutes after drug administration to 5 minutes before auditory test
|
measure of time in minutes between the administration of the drug and the obtaining of a correct sedation (4, 5 or 6 of the score of Ramsey).
|
from 5 minutes after drug administration to 5 minutes before auditory test
|
time of vigilance recovery
Time Frame: from 5 minutes after auditory test to 5 minutes after the patient wake up (Aldrete score equal to 9)
|
measure the time between the end of the examination, (defined by the end of the recording and the disconnection of the electrodes) and the recovery of the vigilance of the child , evaluated by the Aldrete score .
A score of 9 or more determines a correct recovery of alertness and the possibility of returning home.
The child will be reevaluated every 10 minutes until this score is reached.
|
from 5 minutes after auditory test to 5 minutes after the patient wake up (Aldrete score equal to 9)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ana GIORDANO, MD, Hôpitaux Pédiatriques de Nice CHU-Lenval
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- 17-HPNCL-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Auditory Brainstem Response
-
Children's Hospital Medical Center, CincinnatiCompletedAuditory Brainstem ResponseUnited States
-
Pontificia Universidade Catolica de Sao PauloCompletedAuditory Brainstem Response in Children | Sedation With Chloral HydrateBrazil
-
CHU de ReimsCompletedBrainstem ResponseFrance
-
VA Loma Linda Health Care SystemNational Institute on Deafness and Other Communication Disorders (NIDCD)TerminatedAuditory Training and Auditory Efferent SystemUnited States
-
Cantonal Hospital of St. GallenRecruitingSurgery | Brainstem Lesion | Intraoperative Neurophysiologic MonitoringSwitzerland
-
Helsinki University Central HospitalTurku University Hospital; Oulu University Hospital; Kuopio University Hospital; Tampere University HospitalCompletedBrainstem GliomaFinland
-
University of Massachusetts, AmherstCompleted
-
National Institute of Neurological Disorders and...Completed
-
Institut PasteurInstitut de l'AuditionNot yet recruitingAuditory PerceptionBelgium, France
-
University of Sao PauloCompletedAuditory Perception | PsychoacousticsBrazil
Clinical Trials on Dexmedetomidine Hydrochloride
-
Ciusss de L'Est de l'Île de MontréalRecruiting
-
Sunnybrook Health Sciences CentreUniversity Health Network, Toronto; McMaster University; London Health Sciences...RecruitingMental Disorders | Nervous System Diseases | Neurologic Manifestations | Delirium | Confusion | Neurobehavioral Manifestations | Neurocognitive Disorders | Cognitive Dysfunction | Dexmedetomidine | Molecular Mechanisms of Pharmacological Action | Signs and Symptoms | Physiological Effects of Drugs | Analgesics,... and other conditionsCanada
-
Sunnybrook Health Sciences CentreActive, not recruitingDepression | Delirium | Cognitive Impairment | Postoperative Cognitive Dysfunction | DexmedetomidineCanada
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingPostoperative Complications | Anesthesia Recovery PeriodChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedPreoperative SedationChina
-
Shanghai Hengrui Pharmaceutical Co., Ltd.CompletedPreoperative Sedation of ChildrenChina
-
The First Affiliated Hospital with Nanjing Medical...CompletedPostoperative Pain | Breast Feeding | Analgesia ObstetricalChina
-
Eye & ENT Hospital of Fudan UniversityCompletedAgitated; State, Acute Reaction to StressChina
-
Cairo UniversityCompletedPostoperative Nausea and Vomiting | Head and Neck SurgeriesEgypt
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingChronic Obstructive Pulmonary Disease | Dexmedetomidine | Respiratory Function TestsChina